Publicaciones en colaboración con investigadores/as de Novartis (Sweden) (6)

2008

  1. Public health value of fixed-dose combinations in hypertension

    Blood Pressure, Vol. 17, Núm. SUPPL. 1, pp. 5-14

2007

  1. Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial

    Journal of Hypertension, Vol. 25, Núm. 7, pp. 1473-1479

2005

  1. 24-Hour ambulatory blood-pressure effects of valsartan & hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: A VAST sub-study

    Blood Pressure Monitoring, Vol. 10, Núm. 2, pp. 85-91

  2. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: The VAST study

    Clinical Therapeutics, Vol. 27, Núm. 5, pp. 578-588

2000

  1. Safety of the combination of valsartan and benazepril in patients with chronic renal disease

    Journal of Hypertension, Vol. 18, Núm. 1, pp. 89-95

1999

  1. Receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits

    Hypertension, Vol. 34, Núm. 4 II, pp. 969-975